0.415
0.00 (0.00%)
| Previous Close | 0.415 |
| Open | 0.420 |
| Volume | 6,739,210 |
| Avg. Volume (3M) | 7,448,819 |
| Market Cap | 759,292,288 |
| Price / Sales | 1.17 |
| Price / Book | 7.83 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 |
| Operating Margin (TTM) | -8,467.07% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | -0.10% |
| Total Debt/Equity (MRQ) | 0.94% |
| Current Ratio (MRQ) | 10.63 |
| Operating Cash Flow (TTM) | -34.93 M |
| Levered Free Cash Flow (TTM) | -26.79 M |
| Return on Assets (TTM) | -34.35% |
| Return on Equity (TTM) | -56.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BOTANIX FPO [BOT] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
|
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 13.15% |
| % Held by Institutions | 14.17% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |